DK0597033T3 - IGF-1 til forbedring af den neurale tilstand - Google Patents
IGF-1 til forbedring af den neurale tilstandInfo
- Publication number
- DK0597033T3 DK0597033T3 DK92917908.3T DK92917908T DK0597033T3 DK 0597033 T3 DK0597033 T3 DK 0597033T3 DK 92917908 T DK92917908 T DK 92917908T DK 0597033 T3 DK0597033 T3 DK 0597033T3
- Authority
- DK
- Denmark
- Prior art keywords
- nervous system
- central nervous
- igf
- improve
- analogues
- Prior art date
Links
- 230000001537 neural effect Effects 0.000 title abstract 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 title 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 abstract 3
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 abstract 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 abstract 2
- 230000006378 damage Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000004498 neuroglial cell Anatomy 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000002536 noncholinergic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Color Image Communication Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ23921191 | 1991-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0597033T3 true DK0597033T3 (da) | 1997-06-02 |
Family
ID=19923685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK92917908.3T DK0597033T3 (da) | 1991-08-01 | 1992-08-03 | IGF-1 til forbedring af den neurale tilstand |
Country Status (9)
Country | Link |
---|---|
US (2) | US5714460A (el) |
EP (1) | EP0597033B1 (el) |
AT (1) | ATE151293T1 (el) |
CA (1) | CA2114251C (el) |
DE (1) | DE69218948T2 (el) |
DK (1) | DK0597033T3 (el) |
ES (1) | ES2101865T3 (el) |
GR (1) | GR3023874T3 (el) |
WO (1) | WO1993002695A1 (el) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6440928B1 (en) | 1988-12-06 | 2002-08-27 | Colorado State University Research Foundation | Method for treating diabetic neuropathy with NGF |
US6693076B1 (en) * | 1989-06-05 | 2004-02-17 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
US6723699B1 (en) * | 1989-06-05 | 2004-04-20 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
US6310040B1 (en) * | 1991-11-08 | 2001-10-30 | Cephalon, Inc. | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs |
HU217543B (hu) * | 1992-06-12 | 2000-02-28 | Albert Einstein College Of Medicine Of Yeshiva University | Eljárás perifériás neuropátia kezelésére és megelőzésére alkalmas gyógyászati készítmények előállítására, valamint inzulinszerű növekedési faktor I-et és kemoterápiás szert tartalmazó gyógyászati készítmények |
US5420112A (en) * | 1992-06-12 | 1995-05-30 | Lewis; Michael E. | Prevention and treatment of peripheral neuropathy |
US20070078089A1 (en) * | 1992-07-06 | 2007-04-05 | Ishii Douglas N | Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II |
SE9301667D0 (sv) * | 1993-05-14 | 1993-05-14 | Kabi Pharmacia Ab | New use |
CA2176708A1 (en) * | 1993-11-15 | 1995-05-26 | Christopher A. Maack | Method of treating neurological disorders |
WO1995017204A1 (en) | 1993-12-23 | 1995-06-29 | Auckland Uniservices Limited | Composition and methods to improve neural outcome |
US6812208B2 (en) | 1993-12-23 | 2004-11-02 | Neuronz Ltd. | Methods to improve neural outcome |
US5656605A (en) * | 1994-01-26 | 1997-08-12 | Institute Of Molecular Biology, Inc. | Device to promote drug-induced nerve regeneration |
SE9402332D0 (sv) * | 1994-07-01 | 1994-07-01 | Pharmacia Ab | Igf-1 |
US5712249A (en) * | 1994-09-08 | 1998-01-27 | Ciba-Geigy Corporation | Use of insulin-like growth factors I and II for inhibition of inflammatory response |
US5965531A (en) * | 1995-08-31 | 1999-10-12 | National Institutes Of Health | Method of reducing perivascular lesions using insulin-like growth factor I |
EP0874641B1 (en) * | 1995-12-13 | 2003-04-09 | Aurogen Incorporated | Igf-i and -ii for the treatment of diseases of the central nervous system |
US6025368A (en) * | 1997-02-25 | 2000-02-15 | Celtrix Pharmaceuticals, Inc. | Method for treating the symptoms of chronic stress-related disorders using IGF |
US6514937B1 (en) | 1997-02-25 | 2003-02-04 | Celtrix Pharmaceuticals, Inc. | Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3 |
US6015786A (en) | 1997-02-25 | 2000-01-18 | Celtrix Pharmaceuticals, Inc. | Method for increasing sex steroid levels using IGF or IGF/IGFBP-3 |
US6420518B1 (en) | 1997-04-04 | 2002-07-16 | Genetech, Inc. | Insulin-like growth factor agonist molecules |
US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
US6187906B1 (en) * | 1997-08-11 | 2001-02-13 | Aukland Uniservices Limited | Methods to improve neural outcome |
WO1999020299A1 (en) * | 1997-10-17 | 1999-04-29 | Spencer E Martin | Human urinary incontinence and methods of treatment |
US6627746B1 (en) | 1998-04-17 | 2003-09-30 | Exelixis, Inc. | Nucleic acids and proteins of C. elegans insulin-like genes and uses thereof |
WO1999065509A1 (en) * | 1998-06-15 | 1999-12-23 | Neuronz Limited | Regulation of tyrosine hydroxylase |
AU762351B2 (en) | 1999-01-06 | 2003-06-26 | Genentech Inc. | Insulin-like growth factor (IGF) I mutant variants |
DE60042550D1 (de) * | 1999-01-06 | 2009-08-27 | Genentech Inc | Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i) |
AU4503801A (en) * | 1999-10-27 | 2001-06-04 | Chiron Corporation | Temperature dependent neuronal rescue |
ES2301547T3 (es) * | 2000-05-16 | 2008-07-01 | Genentech, Inc. | Tratamiento de trastornos del cartilago. |
CN1469752A (zh) * | 2000-08-29 | 2004-01-21 | 通过给予igf结构类似物治疗中枢神经系统疾病的方法 | |
WO2003049761A1 (en) * | 2000-12-08 | 2003-06-19 | Neuronz Limited | Use of insuline-like growth factor-i for promoting remyelination of axons |
EP1772464B1 (en) * | 2001-02-09 | 2009-08-12 | Genentech, Inc. | Methods of identifying indirect agonists of IGF-1 |
US6682753B2 (en) * | 2001-03-23 | 2004-01-27 | Neuronz Limited | Methods for promoting weight gain using GPE-related compounds |
US20070004641A1 (en) * | 2001-05-24 | 2007-01-04 | Neuren Pharmaceuticals Limited | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate |
US7605177B2 (en) | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
ES2325983T3 (es) | 2001-05-24 | 2009-09-28 | Neuren Pharmaceuticals Limited | Analogos y peptidomimeticos de gpe. |
US6914049B2 (en) | 2001-09-18 | 2005-07-05 | Bioexpertise, Llc | IGF-binding protein-derived peptide or small molecule |
EP1435986B1 (en) * | 2001-09-18 | 2008-01-02 | Bioexpertise, Llc | Igf-binding protein-derived peptide |
US7232798B2 (en) * | 2001-11-13 | 2007-06-19 | Tran Loi H | Neuroprotection and neuroegenisis by administering cyclic prolyl glycine |
GB0202906D0 (en) * | 2002-02-07 | 2002-03-27 | Univ London | Prevention of myocardial damage |
EP1667521B1 (en) | 2003-09-12 | 2011-12-07 | Tercica, Inc. | Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency |
AU2004278311A1 (en) * | 2003-10-03 | 2005-04-14 | Genentech, Inc. | IGF binding proteins |
US7220729B2 (en) * | 2004-05-10 | 2007-05-22 | Academia Sinica | Huntington's Disease Treatment |
EP1674113A1 (en) | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
WO2006097682A1 (en) * | 2005-03-18 | 2006-09-21 | Ucl Business Plc | Mechano growth factor peptides and their use |
EP2012815A4 (en) * | 2006-04-14 | 2009-12-09 | Massachusetts Inst Technology | IDENTIFICATION AND MODULATION OF MOLECULAR PATHWAYS THAT INDUCE THE PLASTICITY OF THE NERVOUS SYSTEM |
JP4958975B2 (ja) | 2006-08-31 | 2012-06-20 | エフ.ホフマン−ラ ロシュ アーゲー | インスリン様増殖因子iの製造方法 |
CL2007002502A1 (es) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
EP2164509A1 (en) * | 2007-06-08 | 2010-03-24 | Massachusetts Institute of Technology | Igf for the treatment of rett syndrome and synaptic disorders |
WO2009121551A1 (en) * | 2008-04-03 | 2009-10-08 | F. Hoffmann-La Roche Ag | Pegylated insulin-like-growth-factor assay |
AU2009231394B2 (en) * | 2008-04-03 | 2013-09-05 | F. Hoffmann-La Roche Ag | Use of PEGylated IGF-I variants for the treatment of neuromuscular disorders |
US20110152188A1 (en) | 2009-12-23 | 2011-06-23 | Hanns-Christian Mahler | Pharmaceutical compositions of igf/i proteins |
EP3299023A4 (en) * | 2015-05-21 | 2019-03-20 | Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences | MESENCHYMAL SUBSTITUTE CELL CULTIVATED IN HYPOXIA AND USE THEREOF |
KR102245539B1 (ko) | 2018-02-12 | 2021-04-29 | 주식회사 지앤피바이오사이언스 | 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물 |
MA53500A (fr) | 2018-05-15 | 2021-08-18 | Lloyd Hung Loi Tran | Composition d'agent thérapeutique et procédé d'utilisation, pour le traitement d'un trouble cognitif léger, de la dépression et de troubles psychologiques |
WO2021005604A1 (en) | 2019-07-11 | 2021-01-14 | Opko Biologics Ltd. | Long-acting igf-1 or igf-1 variants and methods of producing same |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8703625D0 (sv) * | 1987-09-18 | 1987-09-18 | Kabivitrum Ab | New medical use |
US5817623A (en) | 1995-03-06 | 1998-10-06 | Univ Colorado State Res Found | Method for treating diabetic peripheral neuropathy with IGF-I or IGF-II |
US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
WO1991002067A1 (en) * | 1989-07-27 | 1991-02-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Regulation of nerve growth factor synthesis in the central nervous system |
US5219837A (en) * | 1990-06-21 | 1993-06-15 | Trustees Of The University Of Pennsylvania | Method of stimulating myelination of cells |
US5861373A (en) * | 1991-08-01 | 1999-01-19 | Genentech, Inc | IGF-1 to improve the neural condition |
US20070078089A1 (en) | 1992-07-06 | 2007-04-05 | Ishii Douglas N | Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II |
-
1992
- 1992-08-03 DK DK92917908.3T patent/DK0597033T3/da active
- 1992-08-03 EP EP92917908A patent/EP0597033B1/en not_active Revoked
- 1992-08-03 DE DE69218948T patent/DE69218948T2/de not_active Revoked
- 1992-08-03 WO PCT/US1992/006389 patent/WO1993002695A1/en not_active Application Discontinuation
- 1992-08-03 ES ES92917908T patent/ES2101865T3/es not_active Expired - Lifetime
- 1992-08-03 AT AT92917908T patent/ATE151293T1/de not_active IP Right Cessation
- 1992-08-03 CA CA002114251A patent/CA2114251C/en not_active Expired - Lifetime
-
1995
- 1995-06-02 US US08/460,365 patent/US5714460A/en not_active Ceased
-
1997
- 1997-06-24 GR GR970401517T patent/GR3023874T3/el unknown
-
2003
- 2003-06-27 US US10/606,745 patent/USRE43982E1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1993002695A1 (en) | 1993-02-18 |
USRE43982E1 (en) | 2013-02-05 |
DE69218948D1 (de) | 1997-05-15 |
CA2114251C (en) | 2007-11-06 |
DE69218948T2 (de) | 1997-07-31 |
CA2114251A1 (en) | 1993-02-18 |
GR3023874T3 (en) | 1997-09-30 |
EP0597033B1 (en) | 1997-04-09 |
US5714460A (en) | 1998-02-03 |
EP0597033A1 (en) | 1994-05-18 |
ES2101865T3 (es) | 1997-07-16 |
ATE151293T1 (de) | 1997-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0597033T3 (da) | IGF-1 til forbedring af den neurale tilstand | |
HK1048058A1 (zh) | 肝臟選擇性的藥用活性物 | |
DE69230112T2 (de) | Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin | |
HK1003978A1 (en) | Composition for the treatment of schizophrenia | |
CA2122058A1 (en) | Tgf-beta to improve neural outcome | |
PT97785A (pt) | Metodo para a tratamento da impotencia utilizando, por exemplo, doxazosina | |
MY131805A (en) | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis. | |
ZA911496B (en) | Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders | |
BR9708287A (pt) | Processo para tratar ou prevenir um distúrbio do sistema nervoso central em um ser humano, para eliciar um efeito antiemético em um ser humano e para tratar um estado de doença em um ser humano, composição farmacêutica para tratar de distúrbios do sistema nervoso central em um ser humano, e, forma de dosagem unitária farmacêutica | |
ES2160643T3 (es) | Composiciones que contienen g-csf y proteina de union al tnf. | |
DE69800859T2 (de) | Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen | |
EP0744176A3 (en) | Methods for inhibiting bone loss | |
CA2108330A1 (en) | Enhancer for the Antianemia Effect of Erythropoietin and Method of Augmenting the Antianemia Effect of Erythropoietin | |
DE69307702D1 (de) | Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit | |
MD1296G2 (ro) | Metoda Nicolau de tratament al lichenului plan bucal | |
NO961180L (no) | Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom | |
SG49645A1 (en) | A method of treating liver disease and like indications with vasodilating agents | |
IL103499A0 (en) | Pharmaceutical compositions for treating anxiety in benzodiazepine withdrawn patients | |
IT1264428B1 (it) | Composizioni farmaceutiche per il trattamento della psoriasi | |
UA10335A (uk) | Спосіб корекції порушеhь обміhу кальцію у хворих hа сиhдром рейтера хламідійhої етіології | |
RU93050675A (ru) | Способ коррекции психофизиологического состояния человека | |
MY110416A (en) | Composition for the treatment of schizophrenia. |